Hot melt extrusion beats batch in cost

In drug-making operations, use of hot melt extrusion, a continuous processing technology, tops batch processing by requiring less offline testing and fewer operator interventions, which can yield improved product quality. It requires no hazardous solvents or water or drying equipment. The technique is compatible with process analytical technology and scales easily. Though it remains an uncommon way of manufacturing drugs, tech developments are making it a more attractive process option. Article

Suggested Articles

AbbVie will soon own Allergan’s prized Botox franchise, and along with its roughly $4 billion in sales, it will get a new $176 million plant.

Merck KGaA has big plans for a site in Switzerland where it intends to knit together biologics development and manufacturing. 

The FDA has found some issues with Biocon’s small molecule plant in Bengaluru, India.